Glucagon-like peptide 1 (GLP-1)

Müller, Timo D.; Finan, Brian; Bloom, Stephen R.; D’Alessio, David A.; Drucker, Daniel J.; Flatt, Peter R.; Fritsche, Andreas; Gribble, Fiona M.; Grill, Harvey J.; Habener, Joel F.; Holst, Jens J.; Langhans, Wolfgang; Meier, Juris J.; Nauck, Michael A.; Pérez–Tilve, Diego; Pocai, Alessandro; Reimann, Frank; Sandoval, Darleen A.; Schwartz, Thue W.; Seeley, Randy J.; Stemmer, Kerstin; Tang‐Christensen, Mads; Woods, Stephen C.; DiMarchi, Richard D.; Tschöp, M.

doi:10.1016/j.molmet.2019.09.010

reviewMolecular MetabolismSep 30, 2019GOLD OA

Glucagon-like peptide 1 (GLP-1)

TDTimo D. Müller BFBrian Finan SRStephen R. Bloom DADavid A. D’Alessio DJDaniel J. Drucker

Heinrich Heine University Düsseldorf · German Center for Diabetes Research · +31 more institutions

PubMed

Indexed incrossrefdatacitedoajpubmed

Abstract

BACKGROUND: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based…

Citation impact

1,701

total citations

FWCI: 89.58
Percentile: 100%
References: 1,012

Citations per year

Authors

25

Topics & keywords

Topics

Keywords

Glucagon-like peptide-1
Glucagon-like peptide-2
Glucagon
Proglucagon
Incretin
Peptide
Chemistry
Internal medicine

No related works found for this paper.